Iterum Therapeutics (ITRM)
1.26
-0.03 (-2.33%)
At close: Mar 28, 2025, 3:59 PM
1.27
0.21%
Pre-market: Mar 31, 2025, 04:24 AM EDT
-2.33% (1D)
| Bid | 1.22 |
| Market Cap | 43.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -43.49M |
| EPS (ttm) | -1.26 |
| PE Ratio (ttm) | -1 |
| Forward PE | -1.82 |
| Analyst | Buy |
| Ask | 1.32 |
| Volume | 180,746 |
| Avg. Volume (20D) | 475,848 |
| Open | 1.32 |
| Previous Close | 1.29 |
| Day's Range | 1.25 - 1.32 |
| 52-Week Range | 0.81 - 3.02 |
| Beta | 2.44 |
About ITRM
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company ...
Industry Biotechnology
Sector Healthcare
IPO Date May 25, 2018
Employees 9
Stock Exchange NASDAQ
Ticker Symbol ITRM
Website https://www.iterumtx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ITRM stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 295.26% from the latest price.
Stock Forecasts5 months ago
+60.68%
Iterum Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
7 months ago
+11.32%
Iterum Therapeutics shares are trading higher after the company announced it will receive gross proceeds of $7.4M from the expiration and results of its rights offering.
